XORTX plans Health Canada CTA filing for gout candidate XRx-026

XORTX Therapeutics has outlined plans to file a Clinical Trial Application (CTA) with Health Canada for XRx-026, its proprietary oxypurinol formulation branded as XORLO, which is being developed as a treatment for gout. The NASDAQ-listed company said the Canadian filing is designed to run in parallel with its planned New Drug Application to the US Food and Drug Administration, with the aim of generating clinical data more efficiently and at lower cost.

The CTA covers part one of the XRX-OXY-102 study, a two-part clinical programme that will characterise the commercial tablet formulation of XORLO and build on previously reported positive results. XORTX did not provide a target filing date for the CTA or disclose the anticipated timeline for the NDA submission.

Clinical rationale and competitive landscape

XORLO is a formulated version of oxypurinol, a xanthine oxidase inhibitor (XOI) and the active metabolite of allopurinol, the established first-line standard of care for gout. XORTX's case for XRx-026 rests on an identifiable, if relatively narrow, unmet need: an estimated 3 to 5 per cent of gout patients cannot tolerate allopurinol, and the principal alternative XOI, febuxostat, now carries an FDA-mandated boxed warning for cardiovascular risk following a 2019 label update. That warning has significantly eroded febuxostat's commercial position after peak annual net sales of more than US$450 million.

The gout treatment market is not without other competitors. Several companies have investigated uricolytics such as pegloticase for refractory cases, and a number of academic and biotech groups are exploring novel urate-lowering targets. However, the XOI segment itself is relatively underpopulated following febuxostat's decline, which creates a plausible commercial opening for a well-tolerated alternative, provided XORLO can demonstrate the differentiated safety profile the company claims.

Regulatory strategy and commercialisation outlook

Co-chief executive Allen Davidoff said the dual-jurisdiction approach was intended to make more efficient use of capital and personnel, and to expand patient access internationally. The company also disclosed that it has received increased enquiries from potential commercialisation partners across several jurisdictions, though it has not entered into any agreements and cautioned that there is no certainty any discussions will result in a transaction.

The decision to conduct part one of XRX-OXY-102 in Canada is a pragmatic regulatory play. Health Canada's CTA process can in some cases offer faster study start-up timelines than an IND-governed trial in the United States, particularly for companies seeking to advance with constrained resources. The data generated would then be submitted to the FDA as part of the NDA package, a cross-recognition approach that is accepted in principle but still subject to agency agreement on study design.

Gout prevalence is rising globally, with published modelling suggesting cases could increase by around 70 per cent over the next 25 years, driven by ageing populations, dietary patterns and the growing burden of metabolic syndrome. Whether XORTX can bring XORLO to market and capture a meaningful share of that opportunity will depend heavily on the XRX-OXY-102 results and the FDA's view of the NDA package. The company said it would provide further updates as both filings advance.